[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cocrystal Pharma Inc (COCP)

Cocrystal Pharma Inc (COCP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cocrystal Pharma Inc 19805 N. CREEK PARKWAY BOTHELL WA 98011 USA

www.cocrystalpharma.com Employees: 10 P: 877-262-7123

Sector:

Medical

INDUSTRY GROUPING:

Medical - Biomedical

Description:

Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside replication inhibitor of HepC. Phase 1b studies in HepC infected patients showed the largest reduction in viral load of any non-nucleoside inhibitor tested to date. The next step for CC-31244 is clinical trials as part of a cocktail for ultra-short therapy of 2 to 6 weeks. The lead candidate for influenza has advanced to IND-enabling studies. It is effective in animal models against both the pandemic and seasonal strains of influenza. In addition, the Company has a pipeline of promising early preclinical programs. Two private investors own approximately 48% of the Company.

Key Statistics

Overview:

Market Capitalization, $K 14,063
Enterprise Value, $K 6,963
Shares Outstanding, K 13,787
Float, K 8,355
% Float 60.60%
Short Interest, K 410
Short Float 2.97%
Days to Cover 3.77
Short Volume Ratio 0.45
% of Insider Shareholders 39.40%
% of Institutional Shareholders 6.72%

Financials:

Annual Sales, $ 0 K
Annual Net Income, $ -8,830 K
Last Quarter Sales, $ 230 K
Last Quarter Net Income, $ -2,300 K
EBIT, $ -9,040 K
EBITDA, $ -8,660 K

Growth:

1-Year Return -35.39%
3-Year Return -61.19%
5-Year Return -92.63%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth 61.76%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.17 on 05/15/26
Next Earnings Date 08/13/26
Earnings Per Share ttm -0.73
EPS Growth vs. Prev Qtr 0.00%
EPS Growth vs. Prev Year 26.09%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-12 on 10/11/22

COCP Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -150.61%
Return-on-Assets % -97.86%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales 53.22
Price/Cash Flow N/A
Price/Book 3.48
Book Value/Share 0.30
Interest Coverage -1.23
60-Month Beta 1.41
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.